BHCM
CRVS icon

Brevan Howard Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Brevan Howard Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Buy
+167,971
New +$2.68M 0.02% 476
2025
Q4 		– Sell
-15,300
Closed -$113K – 1890
2025
Q3 		$113K Buy
+15,300
New +$78.3K ﹤0.01% 1854
2025
Q2 		– Sell
-21,738
Closed -$69.1K – 1868
2025
Q1 		$69.1K Buy
+21,738
New +$102K ﹤0.01% 1074

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brevan Howard Capital Management's CRVS Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 167,971 shares worth $2.46M. The stake represents 0.02% of the portfolio and ranks #476 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CRVS as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in CRVS in Q1 2025 and has held it in 3 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Brevan Howard Capital Management held 167,971 shares of Corvus Pharmaceuticals worth $2.46M as of Q1 2026.
  • Corvus Pharmaceuticals was a new Brevan Howard Capital Management position in Q1 2026.
  • Corvus Pharmaceuticals made up 0.02% of Brevan Howard Capital Management's portfolio in Q1 2026, its #476 holding.
  • Brevan Howard Capital Management first reported a position in Corvus Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.